PV Bulletin

Submission of Post Approval Changes Applications of Registration Certificate and Import Licence of Human Vaccines and Anti-sera through SUGAM Portal

CDSCO mandates online applications for post-approval changes for vaccines in India.

Primary source: BA/BE

PV Impact Brief

Urgency: HighConfidence: high

What changed

CDSCO mandated the transition to the SUGAM online portal for all applications regarding post-approval changes of human vaccines and anti-sera, effective from June 24, 2026.

Why it matters

This change streamlines the submission process, enhancing efficiency and regulatory compliance for vaccine-related safety updates in India.

Action needed

MAHs must update their application submission procedures to utilize the SUGAM portal for all relevant post-approval changes from June 24, 2026.

Relevant for
Regulatory Intelligence LeadLabeling LeadQPPV
Processes impacted
Country ComplianceLabeling
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Policy change details

Document type
Circular
Policy status
effective
Publication date
2026-06-24
Policy change
CDSCO mandated the use of the SUGAM online portal for submitting applications related to post-approval changes for registration certificates and import licenses of human vaccines and anti-sera.

Key changes

Transition from manual/offline submissions to mandatory online filings through the SUGAM portal for all vaccine-related post-approval changes.

Affected workflows

Country ComplianceLabeling

Responsible groups

Regulatory AffairsPV Operations

PV impact

Safety-related variations and updates to product information for vaccines in India must now be processed through the SUGAM portal, requiring MAHs to update their submission procedures.

View regulator source

Source document details

Exact policy details

Submission of Post Approval Changes Applications
Effective from 2026-Jun-24
Applies to: Human Vaccines and Anti-sera
Submission of Post Approval Changes Applications of Registration Certificate and Import Licence of Human Vaccines and Anti-sera through SUGAM Portal · p. 1 · High · Source

Extracted documents

Unable to extract linked source document: https://cdsco.gov.in/opencms/opencms/system/modules/CDSCO.WEB/elements/download_file_division.jsp

Evidence and confidence

Confidence: highSource updated: Jun 26, 2026

Full briefing

Practical implication

MAHs must update their application submission procedures to utilize the SUGAM portal for all relevant post-approval changes from June 24, 2026.

The Central Drugs Standard Control Organisation (CDSCO) has implemented a new requirement mandating that all applications related to post-approval changes for registration certificates and import licenses of human vaccines and anti-sera be submitted exclusively through the SUGAM online portal. This shift from manual to online submissions includes safety-related updates and variations, necessitating that Marketing Authorization Holders (MAHs) revise their submission procedures accordingly.

What changed: CDSCO mandated the transition to the SUGAM online portal for all applications regarding post-approval changes of human vaccines and anti-sera, effective from June 24, 2026.

Why it matters: This change streamlines the submission process, enhancing efficiency and regulatory compliance for vaccine-related safety updates in India.

Practical implication: MAHs must update their application submission procedures to utilize the SUGAM portal for all relevant post-approval changes from June 24, 2026.

View original source

Published from the Firecrawl policy change extraction pipeline.

#Safety Signals#Circular#effective#Central Drugs Standard Control Organisation (CDSCO)#reporting_requirement#policy-change#firecrawl-policy-agent

Related updates for your role

publicFood and Drug Administration (FDA) · United States · Updated Jun 29, 2026

eMDR System Enhancements - Production Deployment

Urgency: High

Update electronic safety reporting systems and pharmacovigilance databases to implement new rules to ensure all submissions use GENC 3-letter country codes and include the required fields as of July 20, 2026.

ICSRCountry ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Notice
Read impact briefarrow_forward
publicTherapeutics Goods Administration · Australia · Updated Jul 20, 2026

Updates on ISO 14155 and N=1 Therapeutics Discussed by TGA

Urgency: High

Investigators need to modify trial protocols and safety reporting mechanisms in line with the latest ISO 14155 updates to ensure compliance for upcoming high-risk clinical trials.

Inspection ReadinessICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Notice
Read impact briefarrow_forward
publicEuropean Medicines Agency (EMA) · European Union · Updated Jul 20, 2026

CHMP Draft Agenda for Public Consultation on Thalassaemia and Sickle Cell Disease Guidelines

Urgency: High

Sponsors and MAHs must review and align safety data collection and reporting protocols with the newly adopted guidelines while preparing for implementation of PRAC recommendations stemming from this meeting.

Signal ManagementICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead
verifiedRegulatory action: Agenda
Read impact briefarrow_forward
publicSwissmedic · Switzerland · Updated Jul 17, 2026

Checklist for the Inspection of Medical Device Vigilance in Hospitals

Urgency: High

Healthcare facilities must utilize the new checklist during inspections to conduct gap analyses and ensure compliance with reporting requirements associated with their vigilance systems.

Inspection ReadinessRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Checklist
Read impact briefarrow_forward